Webinar | June 29, 2021

Utilizing Bayesian Analysis To Make Go/No-Go Decisions In A Platform Trial

Source: Cytel

In recent years, platform clinical trials have gained substantial support and provide an efficient way of testing multiple compounds in a single and consistent framework. In the traditional setting, each new compound requires independent proof-of-concept, phase 2A and 2B trials to be designed and conducted. In this setting patients are often randomized between the new treatment and control, with the same control utilized in many studies. In contrast, platform clinical trials utilize a master protocol with each new compound added through an intervention specific appendix. This innovative approach leverages the common control, patient outcomes and recruitment centers to improve efficiency in terms of operations, analysis and decision making. In this presentation we review platform trials including terminology, protocol structure overview and discuss some of the key advantages. We also share a concept for a platform trial that utilizes Bayesian modeling to make Go/No-Go decisions and discuss the potential benefits and risks of a platform trial.  

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader